Lesion and ulcer medication

• US 6,555,125 B2
• Filed: 10/17/2001
• Issued: 04/29/2003
• Est. Priority Date: 11/30/1999
• Status: Expired due to Term

• Current Assignee: Phillip Campbell
• Original Assignee: Phillip Campbell
• Inventors: Campbell, Phillip
• Primary Examiner(s): TATE, CHRISTOPHER ROBIN
• Application Number:
  US09/982,038
• Publication Number:
  US 20020044956A1
• Time in Patent Office: 559 Days
• Field of Search: 424/195.18, 424/434, 424/435, 424/485, 514/925, 514/928
• US Class Current: 424/435
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/4164 1,3-Diazoles
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/65 Tetracyclines
• CPC Class Codes: A61K 33/30 Zinc; Compounds thereof
• CPC Class Codes: A61K 36/185 Magnoliopsida (dicotyledons)
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/006 Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Abstract

Pharmaceutical compositions are provided which comprise effective amounts of antimicrobials, anti-inflammatories, and antihistamines, to provide an ulcer medication which prevents secondary infections and promotes healing while providing immediate relief from pain. The composition may be used to treat a variety of ulcers including but not limited to intraoral aphthous ulcers and non-oral lesions. The compositions of the present invention may also be combined with materials capable of forming seals over ulcers or lesions to further promote the healing process.

Claims

1. A method of treating intraoral ulcers comprising the steps of first combining at least one antimicrobial agent, at least one anti-inflammatory, at least one antihistamine, and at least one mucoadhesive to create a final composition and applying the final composition to the intraoral ulcer, wherein said antimicrobial component comprises between 25 and 95 weight percent of the active ingredients, said anti-inflammatory component comprises between 0.02 and 0.7 weight percent of the active ingredients, and said antihistamine comprises between about 0.5 and 11 weight percent of the active ingredients.

2. A method as in claim 1 wherein the at least one anti-inflammatory is dexamethasone and the at least one antihistamine is diphenhydramine.

3. A method as in claim 2 wherein the at least one antimicrobial agent is chosen from the group consisting of zinc oxide and tetracycline HCl.

4. A method as in claim 1 wherein the final composition comprises 500 parts tetracycline HCl, 1 part dexamethasone, 17 parts diphenhydramine, and 67 parts zinc oxide.

5. A method as in claim 4 wherein the final composition further comprises 125 parts Metronidazole.

6. A method of treating intraoral ulcers and lesions comprising the steps:

combining at least one antimicrobial agent, at least one anti-inflammatory, and at least one antihistamine to create a pharmaceutical composition wherein said antimicrobial component comprises between 25 and 95 weight percent of the active ingredients, said anti-inflammatory component comprises between 0.02 and 0.7 weight percent of the active ingredients, and said antihistamine comprises between about 0.5 and 11 weight percent of the active ingredients, applying said pharmaceutical composition to an intraoral ulcer or lesion, and applying an adhesive over the pharmaceutical composition.

7. The method as in claim 6 wherein the adhesive comprises a cyanoacrylate formulation.

8. The method as in claim 7 wherein the cyanoacrylate formulation comprises 2-octyl cyanoacrylate.

9. The method as in claim 7 wherein the cyanoacrylate formulation comprises ethyl cyanoacrylate.

10. The method as in claim 6 wherein the pharmaceutical composition further comprises a mucoadhesive.

11. The method as in claim 10 wherein the anti-inflammatory component is dexamethasone and the antihistamine component is diphenydramine.

12. The method as in claim 10 wherein the adhesive comprises a cyanoacrylate formulation.

13. The method as in claim 12 wherein the cyanoacrylate formulation comprises 2-octyl cyanoacrylate.

14. The method as in claim 12 wherein the cyanoacrylate formulation comprises ethyl cyanoacrylate.

15. The method as in claim 7 wherein the anti-inflammatory component is dexamethasone and the antihistamine component is diphenhydramine.

16. The method as in claim 6 wherein the anti-inflammatory component is dexamethasone and the antihistamine component is diphenydramine.

17. The method as in claim 6 wherein said pharmaceutical composition comprises 500 parts tetracycline HCl, 1 part dexamethasone, 17 parts diphenhydramine, and 67 parts zinc oxide.

18. The method as in claim 7 wherein said pharmaceutical composition comprises 500 parts tetracycline HCl, 1 part dexamethasone, 17 parts diphenhydramine, and 67 parts zinc oxide.

19. The method as in claim 8 wherein said pharmaceutical composition comprises 500 parts tetracycline HCl, 1 part dexamethasone, 17 parts diphenhydramine, and 67 parts zinc oxide.

20. The method as in claim 9 wherein said pharmaceutical composition comprises 500 parts tetracycline HCl, 1 part dexamethasone, 17 parts diphenhydramine, and 67 parts zinc oxide.